JP Morgan Chase’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

JP Morgan Chase’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-116,981	Closed	-$450K	–	7819
2023 Q2	$450K	Sell	116,981 -8,680	-7%	-$31.9K	﹤0.01%	4552
2023 Q1	$379K	Sell	125,661 -4,911	-4%	-$17K	﹤0.01%	4668
2022 Q4	$267K	Sell	130,572 -11,687	-8%	-$35.6K	﹤0.01%	4890
2022 Q3	$492K	Sell	142,259 -5,965	-4%	-$27.1K	﹤0.01%	4480
2022 Q2	$624K	Sell	148,224 -8,145	-5%	-$19.2K	﹤0.01%	4423
2022 Q1	$476K	Sell	156,369 -4,156	-3%	-$15.9K	﹤0.01%	4740
2021 Q4	$746K	Sell	160,525 -4,844	-3%	-$33.3K	﹤0.01%	4585
2021 Q3	$1.27M	Sell	165,369 -51,353	-24%	-$392K	﹤0.01%	4126
2021 Q2	$1.86M	Sell	216,722 -27,106	-11%	-$239K	﹤0.01%	3843
2021 Q1	$2.77M	Buy	+243,828	New	+$3.83M	﹤0.01%	3458

Other funds holding DBTX

ACA

Atlas Capital Advisors Jackson, Wyoming $914M AUM

JP Morgan Chase's DBTX Position: Q3 2023 in Review

JP Morgan Chase sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 116,981 shares — an estimated $450K sold.

JP Morgan Chase first reported a position in DBTX in Q1 2021 and held it in 10 quarters. The position peaked at $2.77M in Q1 2021. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

JP Morgan Chase reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
JP Morgan Chase sold 116,981 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $450K.
JP Morgan Chase first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
JP Morgan Chase's Decibel Therapeutics, Inc. Common Stock position peaked at $2.77M in Q1 2021.
1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.